According to Fior Markets latest report, the global anal fistula treatment market would jump USD 810.65 Million by 2025 from USD 590.28 Million in 2017. The market is expected to register a CAGR of 4.75% during the forecast period from 2018-2025. The Asia Pacific market is anticipated to witness the highest growth rate during the evaluation period. Rising incidence of medical conditions such as Crohn’s disease is one of the contributors to the dominance of the region. In addition, increased awareness about these conditions is expected to prompt the anal fistula treatment market during the forecast period.

Global Anal Fistula Treatment Market by Treatment Type (Non-Surgical and Surgical), Application (Intersphincteric, Transsphincteric, Others), End-user (Hospitals and Ambulatory Centers, Clinics), Region” and Global Forecast 2018-2025.


Top companies in the industry include Cook Medical, Becton, Dickinson and Company, Gem srl, KARL STORZ SE & Co. KG, Medtronic plc, TiGenix NV, W. L. Gore & Associates, Inc., biolitec AG, Novartis, Johnson & Johnson, Bristol Myers, Mylan among others.  Developing and developed countries including U.S, Germany, U.K, China and Japan are offering effective and special opportunities. Key players, aimed at securing market share, are taking efforts by focusing on new product developments and venture capital investments. For instance, in 2018 TiGenix & Takeda Pharmaceutical introduced adipose stem cell-based therapy. In Europe, Medtronic is conducting trials for its collagen paste Permacol.

The type segment is categorized into surgical and non-surgical. The surgical segment includes fistulotomy, advancement flap procedures, seton techniques, bioprosthetic plugs, and others. Surgical segment ruling the anal fistula treatment market and registered around USD 306.49 million in 2017. Major factors contributing to the market growth are increasing incidences of fistula induces infections and rise in demand for safe and effective treatment. Application segment comprises intersphincteric, transsphincteric, suprasphincteric, extrasphincteric, and others. Intersphincteric fistula segment is expected to reach the highest CAGR of 5.62%. End user segment is sub-segmented into hospitals & ambulatory surgery centers, clinics, and others. In 2017, the hospital segment accounted for the largest market share. Hospital segment is the key driving factor for the growth of the market because hospitals are the key providers of minimally invasive treatment and anal fistula surgical treatment in several developing countries.


Increasing cases of anal fistula and recurrence rate of treated cases is a major factor driving the market. Other factors responsible for demand include rising demand for safe and effective treatment with no chance of recurrence and fewer side effects. The estimates state that lack of awareness and high cost of treatment could hamper the growth of the market. Moreover, other future growth drivers include increasing demand for anal fistula treatment creating lucrative opportunities and increasing awareness about the treatment in emerging economies.

Customization of the Report:
This report can be customized to meet the client’s requirements. Please connect with our sales team (, who will ensure that you get a report that suits your needs.